TY - JOUR
T1 - A research framework for reducing preventable patient harm
AU - Pronovost, Peter J.
AU - Cardo, Denise M.
AU - Goeschel, Christine A.
AU - Berenholtz, Sean M.
AU - Saint, Sanjay
AU - Jernigan, John A.
N1 - Funding Information:
Potential conflicts of interest. P.J.P. receives grant or contract support from the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health (NIH), the National Patient Safety Agency (NPSA), the Robert Wood Johnson Foundation (RWJF), and the Commonwealth Fund; has received a gift from private philanthropy for work on another study; has received honoraria from various hospitals, health systems, and the Leigh Speakers Bureau to speak about patient safety and quality-related issues; is a consultant for the Association for Professionals in Infection Control and Epidemiology; and receives royalties for his book, Safe Patients, Smart Hospitals. C.A.G. receives grant support from AHRQ and honoraria from various not-for-profit health care organizations and is an unpaid senior advisor to the World Health Organization, Patient Safety Program. S.M.B. receives grant or contract support from AHRQ, NPSA, World Health Organization, Michigan Health and Hospital Association, NIH, and RWJF; receives honoraria from the Speakers Bureau; and holds equity ownership in DocuSys. S.S. receives grant support from the NIH, Department of Veterans Affairs, the RWJF, and receives honoraria or speaking fees from various hospitals, academic medical centers, medical societies, and non-profit foundations (e.g., Michigan Health and Hospital Association, Institute for Healthcare Improvement). All other authors: no conflicts.
PY - 2011/2/15
Y1 - 2011/2/15
N2 - Programs to reduce central line-associated bloodstream infections (CLABSIs) have improved the safety of hospitalized patients. Efforts are underway to disseminate these successes broadly to reduce other types of hospital-acquired infectious and noninfectious preventable harms. Unfortunately, the ability to broadly measure and prevent other types of preventable harms, especially infectious harms, needs enhancement. Moreover, an overarching research framework for creating and integrating evidence will help expedite the development of national prevention programs. This article outlines a 5-phase translational (T) framework to develop robust research programs that reduce preventable harm, as follows: phase T0, discover opportunities and approaches to prevent adverse health care events; phase T1, use T0 discoveries to develop and test interventions on a small scale; phase T2, broaden and strengthen the evidence base for promising interventions to develop evidence-based guidelines; phase T3, translate guidelines into clinical practice; and phase T4, implement and evaluate T3 work on a national and international scale. Policy makers should use this framework to fill in the knowledge gaps, coordinate efforts among federal agencies, and prioritize research funding.
AB - Programs to reduce central line-associated bloodstream infections (CLABSIs) have improved the safety of hospitalized patients. Efforts are underway to disseminate these successes broadly to reduce other types of hospital-acquired infectious and noninfectious preventable harms. Unfortunately, the ability to broadly measure and prevent other types of preventable harms, especially infectious harms, needs enhancement. Moreover, an overarching research framework for creating and integrating evidence will help expedite the development of national prevention programs. This article outlines a 5-phase translational (T) framework to develop robust research programs that reduce preventable harm, as follows: phase T0, discover opportunities and approaches to prevent adverse health care events; phase T1, use T0 discoveries to develop and test interventions on a small scale; phase T2, broaden and strengthen the evidence base for promising interventions to develop evidence-based guidelines; phase T3, translate guidelines into clinical practice; and phase T4, implement and evaluate T3 work on a national and international scale. Policy makers should use this framework to fill in the knowledge gaps, coordinate efforts among federal agencies, and prioritize research funding.
UR - http://www.scopus.com/inward/record.url?scp=79951835511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951835511&partnerID=8YFLogxK
U2 - 10.1093/cid/ciq172
DO - 10.1093/cid/ciq172
M3 - Article
C2 - 21258104
AN - SCOPUS:79951835511
SN - 1058-4838
VL - 52
SP - 507
EP - 513
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 4
ER -